Bayesian Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Bayesian Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,881	Closed	-$135K	–	836
2018 Q1	$135K	Buy	+45,881	New	+$125K	0.03%	525
2017 Q4	–	Sell	-35,875	Closed	-$122K	–	826
2017 Q3	$122K	Buy	+35,875	New	+$99.8K	0.03%	450
2016 Q2	–	Sell	-37,200	Closed	-$124K	–	632
2016 Q1	$124K	Buy	+37,200	New	+$116K	0.12%	303

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bayesian Capital Management's PDLI Position: Q2 2018 in Review

Bayesian Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 45,881 shares — an estimated $135K sold.

Bayesian Capital Management first reported a position in PDLI in Q1 2016 and held it in 3 quarters. The position peaked at $135K in Q1 2018. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Bayesian Capital Management reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Bayesian Capital Management sold 45,881 PDL BioPharma, Inc. shares in Q2 2018, an estimated $135K.
Bayesian Capital Management first reported a position in PDL BioPharma, Inc. in Q1 2016 and held it in 3 quarters.
Bayesian Capital Management's PDL BioPharma, Inc. position peaked at $135K in Q1 2018.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Bayesian Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.